



(51) International Patent Classification:

A61K 39/395 (2006.01) A61K 47/68 (2017.01)
C07K 16/28 (2006.01) C07K 16/18 (2006.01)
A61P 35/00 (2006.01) A61K 39/00 (2006.01)

(21) International Application Number:

PCT/US2020/016381

(22) International Filing Date:

03 February 2020 (03.02.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/801,590	05 February 2019 (05.02.2019)	US
62/824,923	27 March 2019 (27.03.2019)	US
62/879,660	29 July 2019 (29.07.2019)	US
62/882,016	02 August 2019 (02.08.2019)	US
62/934,424	12 November 2019 (12.11.2019)	US

(71) Applicant: SEATTLE GENETICS, INC. [US/US];
21823 30th Drive Southeast, Bothell, Washington 98021 (US).

(72) Inventors: SANDALL, Sharsti; c/o Seattle Genetics, Inc.,
21823 30th Drive Southeast, Bothell, Washington 98021 (US). WESTENDORF, Lori; c/o Seattle Genetics, Inc.,

21823 30th Drive Southeast, Bothell, Washington 98021 (US). LEWIS, Timothy; c/o Seattle Genetics, Inc., 21823 30th Drive Southeast, Bothell, Washington 98021 (US).


(74) Agent: BANKO, Max et al.; Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, California 94304-1018 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: ANTI-CD228 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES

FIG. 22

Colo-853 Melanoma xenograft model
92,000 CD228 molecules

(57) Abstract: Provided are novel anti-CD228 antibodies and antibody-drug conjugates and methods of using such anti-CD228 antibodies and antibody-drug conjugates to treat cancer.

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*